Clinical trials: Placebo Response
ARDS
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis
Sivelestat sodium has been approved for use in patients with SIRS and ALI, but whether it can protect patients with sepsis from developing ARDS remains unknown.The aim of this study was to determine whether sivelestat sodium has…
- Trial name
- NCT04973670
- Testing
- Sivelestat sodium
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Southeast University, China
Schizophrenia
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with…
- Trial name
- NCT00210769
- Testing
- paliperidone ER Oros
- Volunteers
- 203 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Moderate and Severe Plaque Psoriasis
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease…
- Trial name
- NCT00885196
- Testing
- AEB071
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 336 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Cannabis
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
The study will randomly assign Rheumatoid Arthritis (RA) patients on stable RA therapy to either placebo or cannabidiol (CBD). The overall goal of this proposal is to examine the efficacy and safety of CBD treatment as adjunctive…
- Trial name
- NCT04911127
- Testing
- 200mg Cannabidiol by capsules twice daily, 400mg Cannabidiol by capsules twice daily
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of California, Los Angeles
Depressive Disorder, Treatment-Resistant
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate…
- Trial name
- NCT02153502
- Testing
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
- Where
- 32 sites in United States
- Volunteers
- 206 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Photosensitive Epilepsy
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
- Trial name
- NCT00784212
- Testing
- BGG492
- Where
- 4 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
LYT-300 in Healthy Volunteers
Part 1 is a single ascending dose (SAD) trial in healthy volunteers (HV) to assess the safety, tolerability, and pharmacokinetic (PK) profile of orally administered LYT-300.
- Trial name
- NCT05129865
- Testing
- LYT-300
- Where
- Australia
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- PureTech
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
To perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live…
- Trial name
- CAIVT (NCT00192322)
- Testing
- CAIV-T 10^7, CAIVT 10^5, TIV
- Where
- 2 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rheumatoid Arthritis
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with…
- Trial name
- ASPIRA (NCT01851707)
- Testing
- IPI-145
- Where
- 64 sites in Bulgaria, Colombia and 9 more
- Volunteers
- 322 people
- Sponsor
- SecuraBio
Septic Shock, Severe Sepsis
Selenium, as Sodium Selenite, in the Treatment of Septic Shock
Septic shock is a frequent syndrome with a 45% mortality rate despite intensive care unit (ICU) care, where free radicals may play a key role, and a >40% decrease in plasma selenium concentration is observed.
- Trial name
- NCT00207844
- Testing
- Selenium as sodium selenite
- Where
- 7 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier de Meaux
Overweight
Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects
The investigators objective is to carry out a placebo-controlled, dose-response, randomized clinical trial to assess the effects of polyphenols or derived metabolites on cardiovascular disease risk in overweight adult subjects…
- Trial name
- POMEcardio (NCT02061098)
- Testing
- Pomegranate extract-first dose-Group A, Pomegranate extract-first dose-Group B, Pomegranate extract-second dose-Group A
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Research Council, Spain
Asthma
Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma
This is a dose-response study to determine how various measurements of airway inflammation respond to high and low dose FlutiForm®, and compared to placebo.
- Trial name
- FLT2503 (NCT00995800)
- Testing
- Fluticasone propionate / Formoterol fumarate
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Mundipharma Research Limited
Type 2 Diabetes Mellitus (T2DM)
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female…
- Trial name
- NCT01835730
- Testing
- PE0139 Injection
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Impotence, Erectile Dysfunction
The Management of Erectile Dysfunction With Placebo Only
Placebo-controlled randomized clinical trials (RCT) are the gold standard to provide applicable evidence for clinical practice. A vast number of RCTs for treatment of several disorders has shown a mean placebo effect of 30%.
- Trial name
- DAFA06 (NCT00882934)
- Testing
- Induction to efficient treatment, Doubt to the efficacy of treatment, Induction to ineffective treatment
- Volunteers
- 123 people
- Sponsor
- Rio de Janeiro State University
Herpes Zoster
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
- Trial name
- NCT04091451
- Testing
- Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
- Where
- 3 sites in Russia
- Volunteers
- 1,430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.